【摘要】 目的初步评价沙利度胺加联合化疗对恶性浆细胞疾病患者的疗效和毒副作用。方法17例多发性骨髓瘤和5例浆细胞白血病患者,采用沙利度胺联合VAD(T-VAD方案)或CED(T-CED方案)或MP(T-MP方案)治疗2～4疗程,评价其疗效和毒副作用。结果21例可评价疗效的患者,6例(28.6%)获得完全缓解(CR),10例(47.6%)获得部分缓解(PR),总有效率(CR+PR)为76.2%,中位生存时间为48个月。所有患者共接受了86个疗程的治疗,最常见的不良反应为指端麻木感(40.9%),便秘(40.9%),嗜睡(36.4%),水肿(27.3%),未出现一例深静脉血栓(DVT)。结论沙利度胺加联合化疗治疗恶性浆细胞疾病疗效好,毒副作用轻微,易于耐受。更多还原

【Abstract】 Objective To explore the outcome and side-effects in patients with malignant plasma cell diseases treated with thalidomide and combined chemotherapy. Methods 17 patients with multiple myeloma(MM) and 5 patients with plasma cell leukemia(PCL) were treated with the combination of thalidomide and VAD(T-VAD regimen) or CED(T-CED regimen) or MP(T-MP regimen) chemotherapy. Response to treatment and side-effects were evaluated after two or four cycles of treatment. Results On an intention-to-treat basis, 16 of the 21 patients (76.2 %) responded to treatment. Six patients (28.6 %) achieved complete remission(CR) and 10 (47.6 %) achieved partial remission(PR). The median survival time was 48 months. In the entire group of patients, a total of 86 cycles of therapy was given. Major toxicities consisted of numbness (40.9 %), constipation (40.9 %), somnolence (36.4 %) and edema (27.3 %), and no one patient experienced deep vein thrombosis(DVT). Conclusions Thalidomide combined combination chemotherapy is an effective and relatively well-tolerated treatment for patients with malignant plasma cell diseases.更多还原